

Product Datasheet

Duvelisib

Catalog No. **BP-02331** · CAS **1201438-56-3** · Form **free base** · Physical state **solid** · Color **Off-white to gray** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PI3K	Research area Cancer
-----------------------	--------------------------------

Molecular formula **C₂₂H₁₇ClN₆O**

Molecular weight **416.8630**

STRUCTURE



DESCRIPTION

Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with K_i and IC_{50} of 23 pM/243 pM and 1 nM/50 nM in cell-free assays.

BIOLOGICAL ACTIVITY

Duvelisib (IPI-145) is a novel and selective PI3K δ/γ inhibitor with IC_{50} of 23 pM and 243 pM, respectively. IPI-145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Duvelisib (IPI-145) suppresses murine/human B-cell proliferation with EC_{50} of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC_{50} of 9.5 nM. IPI-145 was well tolerated and clinically active in a broad range of malignancies, including iNHL. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model.

SOLUBILITY

Soluble in DMSO

REFERENCES

- [1]. Pillinger G, et al. Targeting PI3K δ and PI3K γ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. *Oncotarget*. 2016 Jun 28;7(26):39784-39795.
- [2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. *Int J Cancer*. 2015 Nov 1;137(9):2234-42.